These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34569193)

  • 21. Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Wang H; Huang M; Zhao Y; Qi JQ; Chen C; Tang YQ; Qiu HY; Fu CC; Tang XW; Wu DP; Ruan CG; Han Y
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1678-1684. PubMed ID: 28642072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical tolerance test of recombinant human thrombopoietin].
    Zhao Y; Jiang J; Jiao L
    Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1508-11. PubMed ID: 16200777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma.
    Jang G; Ko OB; Kim S; Lee DH; Huh J; Suh C
    Transfusion; 2008 Apr; 48(4):640-6. PubMed ID: 18194384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization.
    Gajewski JL; Rondon G; Donato ML; Anderlini P; Korbling M; Ippoliti C; Benyunes M; Miller LL; LaTemple D; Jones D; Ashby M; Hellmann S; Durett A; Lauppe J; Geisler D; Khouri IF; Giralt SA; Andersson B; Ueno NT; Champlin R
    Biol Blood Marrow Transplant; 2002; 8(10):550-6. PubMed ID: 12434950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-Dose Administration of Recombinant Human Thrombopoietin Mitigates Total Body Irradiation-Induced Hematopoietic System Injury in Mice and Nonhuman Primates.
    Xing S; Shen X; Yang JK; Wang XR; Ou HL; Zhang XW; Xiong GL; Shan YJ; Cong YW; Luo QL; Yu ZY
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1357-1367. PubMed ID: 32758640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study.
    Wu Q; Ren J; Wu X; Wang G; Gu G; Liu S; Wu Y; Hu D; Zhao Y; Li J
    J Crit Care; 2014 Jun; 29(3):362-6. PubMed ID: 24405656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia.
    Wang S; Yang R; Zou P; Hou M; Wu D; Shen Z; Lu X; Li Y; Chen X; Niu T; Sun H; Yu L; Wang Z; Zhang Y; Chang N; Zhang G; Zhao Y
    Int J Hematol; 2012 Aug; 96(2):222-8. PubMed ID: 22753022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma.
    Martin RMG; Ricci MJ; Foley R; Mian HS
    Transfus Apher Sci; 2017 Aug; 56(4):552-557. PubMed ID: 28669690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma].
    Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473
    [No Abstract]   [Full Text] [Related]  

  • 30. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
    Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
    Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.
    Gunn N; Damon L; Varosy P; Navarro W; Martin T; Ries C; Linker C
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):643-8. PubMed ID: 14569560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.
    Liang EC; Muffly LS; Shiraz P; Shizuru JA; Johnston L; Arai S; Frank MJ; Weng WK; Lowsky R; Rezvani A; Meyer EH; Negrin R; Miklos DB; Sidana S
    Transplant Cell Ther; 2021 May; 27(5):405.e1-405.e6. PubMed ID: 33775587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
    Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
    Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis.
    Wang Y; Wang Z; Wu L; Zhang J; Wang J; Yan L
    Ann Hematol; 2013 Dec; 92(12):1695-9. PubMed ID: 23778995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
    Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
    Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.
    Tricot G; Jagannath S; Vesole D; Nelson J; Tindle S; Miller L; Cheson B; Crowley J; Barlogie B
    Blood; 1995 Jan; 85(2):588-96. PubMed ID: 7529066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study.
    Mo H; Liu P; Qin Y; He X; Han X; Yao J; Su W; Zhang S; Tang L; Zhao F; Gui L; Yang S; Yang J; Zhou S; Zhang Z; Shi Y
    Chronic Dis Transl Med; 2021 Sep; 7(3):190-198. PubMed ID: 34505019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
    Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
    Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.